---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-24-000021"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:57:53.789326+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q1 net product rev $365M (+32% YoY); net loss narrows to $0.52/share

## Summary
- Net product revenue $365M, up 32% YoY; TTR franchise $264M (+29%), Rare $101M (+40%).
- GAAP net loss $65.9M ($0.52 per share) vs $174.1M ($1.40) in Q1 2023.
- 2024 guidance reiterated: combined net product revenue $1.4B–$1.5B.
- Zilebesiran: positive KARDIA-2 results; KARDIA-3 initiated, triggering $65M Roche milestone.
- HELIOS-B Phase 3 topline results for vutrisiran on track for late June/early July.

## SEC filing metadata
- accession: 0001178670-24-000021
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000021/0001178670-24-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000021/alny-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-24-000021
- JSON: https://secwatch.observer/filing/0001178670-24-000021.json
- Plain text: https://secwatch.observer/filing/0001178670-24-000021.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported the quarter ended March 31, 2024 results: revenue $365 million, net income GAAP Net loss $65,935 (in thousands), EPS GAAP Net loss per common share - basic and diluted $0.52. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $365 million
  - Net income: GAAP Net loss $65,935 (in thousands)
  - EPS: GAAP Net loss per common share - basic and diluted $0.52
  - Guidance: reaffirmed
  - Result: reported results
  source text: Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity − Achieved First Quarter 2024 Global Net Product Revenues of $365 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000021/0001178670-24-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.